EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieOpen access

A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial

Ximena A Levander iD, Thomas Carmody, Ryan R Cook iD, Jennifer S Potter, Madhukar H Trivedi iD, Philip Todd Korthuis iD, Steven Shoptaw iD

Addiction · 2023

DOI: 10.1111/add.16163 ↗

At a glance

Randomisierte kontrollierte Studie in Addiction, 2023. Written by Ximena A Levander and 6 co-authors. Institution: Oregon Health and Science University, Department of Medicine, Division of General Internal Medicine and Geriatrics, Addiction Medicine Section, Portl…. Major MEDLINE topics: Methamphetamine, Central Nervous System Stimulants. Cited 4 times so far (Crossref); 54 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, NCATS NIH HHS, AHRQ HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Aims Socio‐cultural (gender) and biological (sex)‐based differences contribute to psychostimulant susceptibility, potentially affecting treatment responsiveness among women with methamphetamine use disorder (MUD). The aims were to measure (i) how women with MUD independently and compared with men respond to treatment versus placebo and (ii) among women, how the hormonal method of contraception (HMC) affects treatment responsiveness.

Design

This was a secondary analysis of ADAPT‐2, a randomized, double‐blind, placebo‐controlled, multicenter, two‐stage sequential parallel comparison design trial.

Setting

United States.

Participants

This study comprised 126 women (403 total participants); average age = 40.1 years (standard deviation = 9.6) with moderate to severe MUD.

Interventions

Interventions were combination intramuscular naltrexone (380 mg/3 weeks) and oral bupropion (450 mg daily) versus placebo.

Measurements

Treatment response was measured using a minimum of three of four negative methamphetamine urine drug tests during the last 2 weeks of each stage; treatment effect was the difference between weighted treatment responses of each stage.

Findings

At baseline, women used methamphetamine intravenously fewer days than men [15.4 versus 23.1% days, P = 0.050, difference = −7.7, 95% confidence interval (CI) = −15.0 to −0.3] and more women than men had anxiety (59.5 versus 47.6%, P = 0.027, difference = 11.9%, 95% CI = 1.5 to 22.3%). Of 113 (89.7%) women capable of pregnancy, 31 (27.4%) used HMC. In Stage 1 29% and Stage 2 5.6% of women on treatment had a response compared with 3.2% and 0% on placebo, respectively. A treatment effect was found independently for females and males ( P < 0.001); with no between‐gender treatment effect (0.144 females versus 0.100 males; P = 0.363, difference = 0.044, 95% CI = −0.050 to 0.137). Treatment effect did not differ by HMC use (0.156 HMC versus 0.128 none; P = 0.769, difference = 0.028, 95% CI −0.157 to 0.212).

Conclusions

Women with methamphetamine use disorder receiving combined intramuscular naltrexone and oral bupropion treatment achieve greater treatment response than placebo. Treatment effect does not differ by HMC.

Subjects

MeSH terms (MEDLINE)

MethamphetamineCentral Nervous System StimulantsMalePregnancyHumansFemaleAdultNaltrexoneBupropionDrug Therapy, CombinationDouble-Blind Method

Author keywords

Amphetamine-related disordersbupropionclinical trialgender differencesmethamphetaminenaltrexonesex differenceswomenwomen's health

Substances

MethamphetamineNaltrexoneBupropionCentral Nervous System Stimulants

Authors and institutions

  • Oregon Health and Science University, Department of Medicine, Division of General Internal Medicine and Geriatrics, Addiction Medicine Section, Portland, OR, USA.
  • Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
  • Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Family Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA.

ORCID profiles: Ximena A Levander, Ryan R Cook, Madhukar H Trivedi, Philip Todd Korthuis, Steven Shoptaw

Funding

  • NIDA NIH HHS
  • NCATS NIH HHS
  • AHRQ HHS
  • Agency for Healthcare Research and Quality
  • National Institute on Drug Abuse
  • U.S. Department of Health and Human Services

Cite

APA

Levander, X. A., Carmody, T., Cook, R. R., Potter, J. S., Trivedi, M. H., Korthuis, P. T., & Shoptaw, S. (2023). A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction. https://doi.org/10.1111/add.16163

Vancouver

Levander XA, Carmody T, Cook RR, Potter JS, Trivedi MH, Korthuis PT, et al. A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction. 2023. doi:10.1111/add.16163

BibTeX
@article{Levander2023,
  author = {Levander, Ximena A and Carmody, Thomas and Cook, Ryan R and Potter, Jennifer S and Trivedi, Madhukar H and Korthuis, Philip Todd and Shoptaw, Steven},
  title = {A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial},
  journal = {Addiction},
  year = {2023},
  doi = {10.1111/add.16163}
}
Start for free →